Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes in the Real World Setting (VEDO TDM RWE)

NCT04567628 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04567628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04567628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes in the Real World Setting (VEDO TDM RWE)
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
October 5, 2020
Completion date
September 22, 2021
Enrollment
7,873 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative, crohn disease, inflammatory bowel diseases